Sanofi's new business-unit structure focuses on growth drivers.
Sanofi announced plans on July 15, 2015 to evolve its business with the creation of five, global business units: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur, and Merial. This new structure will be implemented beginning in January 2016, following required legal and social consultation.
"The new organization simplifies and focuses Sanofi to optimize growth," said Olivier Brandicourt, CEO, Sanofi. "This is a necessary step for ensuring that Sanofi's new medicines and vaccines continue to build on our heritage of providing innovative healthcare therapies."
The General Medicines & Emerging Markets Global Business Unit will be led by Peter Guenter and will consist of Sanofi's established products, generics, consumer healthcare, and all pharmaceutical businesses in emerging markets.
The Specialty Care Global Business Unit, to be called Sanofi Genzyme, will be led by David Meeker and will consist of Sanofi's medicines in rare diseases, multiple sclerosis, oncology, and immunology, including the two, investigational biologics, sarilumab and dupilumab.
The Diabetes & Cardiovascular Global Business Unit will be led by Pascale Witz and will consist of Sanofi's Diabetes Care medicines as well as Cardiovascular, including Praluent (alirocumab), which is currently under review by FDA and the European Medicines Agency.
Sanofi Pasteur and Merial are both Global Business Units and will continue to manage their current portfolios of vaccines and animal health products. Olivier Charmeil will continue to lead Sanofi Pasteur, and Carsten Hellmann will continue to lead Merial.
The composition of the Executive Committee remains unchanged.
Source: Sanofi
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.